Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 May;34(5):823–826. doi: 10.1128/aac.34.5.823

Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin.

S L Barriere 1, D H Catlin 1, P L Orlando 1, A Noe 1, R W Frost 1
PMCID: PMC171699  PMID: 2360821

Abstract

Healthy subjects were given single intravenous doses of ciprofloxacin, azlocillin, and the two drugs simultaneously on separate occasions. High-pressure liquid chromatographic analysis was used to assay the concentrations of both drugs in serum and urine. Pharmacokinetic parameters were calculated by noncompartmental methods. The total body (CL), renal (CLR), and nonrenal (CLNR) clearances; steady-state volume of distribution (Vss); and fractional urinary excretion of ciprofloxacin were all markedly decreased with the simultaneous administration of azlocillin. The disposition of azlocillin was unchanged when it was given with ciprofloxacin compared to when it was given alone. The pharmacokinetic parameters (mean +/- standard deviation) of ciprofloxacin given alone versus in combination with azlocillin were as follows: CL, 52.2 +/- 9.2 versus 33.9 +/- 6.0 liters/h (P less than 0.0005); CLR, 26.5 +/- 4.8 versus 16.2 +/- 4.2 liters/h (P less than 0.0005); CLNR, 25.8 +/- 5.5 versus 17.7 +/- 4.0 liters/h (P less than 0.03); Vss, 224 +/- 30 versus 166 +/- 41 liters (P less than 0.01); fractional urinary excretion, 0.56 +/- 0.06 versus 0.43 +/- 0.04 (P less than 0.002), respectively. This interaction resulted in significantly higher and more prolonged concentrations of ciprofloxacin in serum, which may be beneficial in the treatment of serious gram-negative bacterial infections, but it could also produce greater toxicity or result in more pronounced effects on oxidative drug metabolism of other medications.

Full text

PDF
823

Images in this article

825Image
on p.825

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bamberger D. M., Peterson L. R., Gerding D. N., Moody J. A., Fasching C. E. Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model. J Antimicrob Chemother. 1986 Jul;18(1):51–63. doi: 10.1093/jac/18.1.51. [DOI] [PubMed] [Google Scholar]
  2. Drusano G. L., Schimpff S. C., Hewitt W. L. The acylampicillins: mezlocillin, piperacillin, and azlocillin. Rev Infect Dis. 1984 Jan-Feb;6(1):13–32. doi: 10.1093/clinids/6.1.13. [DOI] [PubMed] [Google Scholar]
  3. Johnson M., Miniter P., Andriole V. T. Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis. J Infect Dis. 1987 Apr;155(4):783–788. doi: 10.1093/infdis/155.4.783. [DOI] [PubMed] [Google Scholar]
  4. Kampf D., Borner K., Möller M., Kessel M. Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function. Clin Pharmacol Ther. 1984 Feb;35(2):214–220. doi: 10.1038/clpt.1984.29. [DOI] [PubMed] [Google Scholar]
  5. LeBel M. Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy. 1988;8(1):3–33. doi: 10.1002/j.1875-9114.1988.tb04058.x. [DOI] [PubMed] [Google Scholar]
  6. Peterson L. R., Moody J. A., Fasching C. E., Gerding D. N. In vivo and in vitro activity of ciprofloxacin plus azlocillin against 12 streptococcal isolates in a neutropenic site model. Diagn Microbiol Infect Dis. 1987 Jun;7(2):127–136. doi: 10.1016/0732-8893(87)90030-7. [DOI] [PubMed] [Google Scholar]
  7. Rodondi L. C., Flaherty J. F., Schoenfeld P., Barriere S. L., Gambertoglio J. G. Influence of coadministration on the pharmacokinetics of mezlocillin and cefotaxime in healthy volunteers and in patients with renal failure. Clin Pharmacol Ther. 1989 May;45(5):527–534. doi: 10.1038/clpt.1989.68. [DOI] [PubMed] [Google Scholar]
  8. Webb D. B., Roberts D. E., Williams J. D., Asscher A. W. Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):83–87. doi: 10.1093/jac/18.supplement_d.83. [DOI] [PubMed] [Google Scholar]
  9. Zinner S. H., Dudley M. N. Bactericidal activity of ciprofloxacin alone and in combination with azlocillin in an in-vitro capillary model. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):49–54. doi: 10.1093/jac/18.supplement_d.49. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES